Vas Narasimhan, Getty Images
The big drug hunters: Novartis’ $28B-plus deal spree makes Vas Narasimhan one of the top dealmakers of our time
Novartis CEO Vas Narasimhan talks a careful game when it comes to dealmaking. But his new $9.7 billion MedCo buyout — which gives him a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
